- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00848237
HALO Patient Registry: Ablation of Barrett's Esophagus
HALO Patient Registry: Ablation of Barrett's Esophagus, A Multi-Center Patient Registry
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Summary The HALO Patient Registry provides a framework for treatment and follow-up of patients with Barrett's esophagus (non-dysplastic IM, LGD and HGD). The primary objective is to provide a tool for participating physician investigators to collect outcomes data related to the use of the HALO Ablation Systems.
Protocol Design:
This is a prospective, multi-center patient Registry. Sites may choose to also retrospectively enroll previously treated patients (after obtaining informed consent) and enter retrospective data into case report forms on-line. "Retrospective data collection" is defined as any data other than patient history collected prior to signing of the informed consent. A set of case report forms (CRFs) is provided along with this protocol to track outcomes. The CRFs may be completed and retained on site, but the site is recommended to utilize the internet-based data entry system.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
California
-
Knoxville and other US cities, California, Forenede Stater, 27599-7080
- Gastrointestinal Associates and sites across the US
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Must be a candidate for ablation of Barrett's esophagus with the HALO Ablation System.
- Must agree to the proposed follow-up schedule and provide informed consent for participation.
Exclusion Criteria:
- Pregnancy
- Prior radiation therapy to the esophagus
- Esophageal varices at risk for bleeding
- Prior Heller Myotomy
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Treatment
All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.
|
Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI).
All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Endoscopic Clearance Rate for Barrett's Esophagus-Percentage of Patients With no Endoscopically Visible Barrett's Esophagus at 1 Year Follow-up
Tidsramme: 1 year
|
% of patients with 100 % resolution at 1 year follow-up.
This endpoint is a visual and not reliable or accurate.
A better measure of clearance of Barrett's esophagus is based on biopsies.
|
1 year
|
|
Histological Clearance Rate for Intestinal Metaplasia (CE-IM)
Tidsramme: 1 year
|
Percentage of patients with no histological evidence of intestinal metaplasia at 1 year follow-up
|
1 year
|
|
Histological Clearance Rate for Dysplasia (CE-D)
Tidsramme: 1 year
|
percentage of patients with baseline dysplasia who have no histological evidence of dysplasia at 1 year follow-up
|
1 year
|
|
Percentage of Patients With Sub-squamous Intestinal Metaplasia at 1 Year Follow up
Tidsramme: 1 year
|
Percentage of patients at 1 year follow-up with sub-squamous intestinal metaplasia, with or without dysplasia, that is covered completely by an intact layer of squamous epithelium with no communication with the surface
|
1 year
|
|
Patient Quality of Life Questionnaire Results: Change From Baseline to 12 Month
Tidsramme: 12 month
|
Patient who completed both baseline and follow-up Quality of Life: Scores (0-10) of quality of life at baseline and 12 month follow-up were measured and changes were calculated ( 12 months minus baseline) in: concerns about the condition of esophagus, negative impact on life and esophageal cancer worry.
Scale range is 0-10, 0 is min and 10 is max.
Higher value represent worse outcome (such as higher concern about the condition of esophagus, negative impact on life and higher esophageal cancer worry).
|
12 month
|
|
Adverse Event Incidence
Tidsramme: 12 month
|
Adverse and Serious Adverse event with Definite device relationship
|
12 month
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- B-500
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Barrett Esophagus
-
Digma Medical Ltd.Ikke rekrutterer endnu
-
Erbe Elektromedizin GmbHNAMSA; Kansas City Veteran Affairs Medical Center; Erbe USA IncorporatedAfsluttetBarretts spiserør | Højgradig dysplasi i Barrett-esophagus | Lavgradig dysplasi i Barrett-esophagusForenede Stater
-
Maria Sklodowska-Curie National Research Institute...Centre of Postgraduate Medical EducationAfsluttetBarretts esophagus med lavgradig dysplasi
-
Tomasz RomańczykAfsluttetHeterotopisk maveslimhinde i den proksimale esophagusPolen
-
Johns Hopkins UniversityAmerican Society for Gastrointestinal Endoscopy; Pentax Medical CorporationAfsluttetBarretts esophagus, esophageal intraepithelial neoplasiForenede Stater, Tyskland
-
University Medical Center GroningenAfsluttetSpiserørskræft | Barrett Esophagus | Dysplasi i Barrett EsophagusHolland
-
University Hospital, AntwerpKarolinska University Hospital; Karolinska Institutet; Rigshospitalet, Denmark og andre samarbejdspartnereIkke rekrutterer endnuBarrett Esophagus | Gastroenterologi | Barrett Esophagus Adenocarcinom | Adenocarcinom - GEJ | Gastroenterologisk kræftDanmark, Belgien, Sverige, Irland, Italien, Frankrig, Tyskland
-
Coordinación de Investigación en Salud, MexicoSuspenderetIntestinal Metaplasi | Dysplasi | Barretts esophagus med lavgradig dysplasiMexico
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Nederlandse Barrett REgistratie StichtingRekrutteringBarrett Esophagus | Barrett Esophagus AdenocarcinomHolland
-
International Agency for Research on CancerUniversity of Cambridge; Kilimanjaro Clinical Research InstituteAfsluttet
Kliniske forsøg med Radiofrequency Ablation (HALO Ablation Systems)
-
Hangzhou Valgen Medtech Co., LtdAktiv, ikke rekrutterendeObstruktiv hypertrofisk kardiomyopatiKina
-
Hangzhou Valgen Medtech Co., LtdIkke rekrutterer endnuObstruktiv hypertrofisk kardiomyopatiKina
-
Thermedical, Inc.RekrutteringRefraktær ventrikulær takykardiForenede Stater, Canada
-
Medtronic CardiovascularAfsluttetAtrieflimrenForenede Stater
-
Thermedical, Inc.National Heart, Lung, and Blood Institute (NHLBI)AfsluttetHjertesygdomme | Hjerte-kar-sygdomme | Ventrikulær takykardi | ArytmiForenede Stater
-
Innoblative Designs, Inc.RekrutteringBrystkræft | Brystbevarende kirurgi | Brystkræft - infiltrerende ductal karcinom | ER/PR+HER2NEU | Grad I, II, IIIForenede Stater
-
Pentax MedicalAfsluttetBarretts spiserørForenede Stater, Holland
-
CSA Medical, Inc.AfsluttetLungekræft | MesotheliomForenede Stater
-
Pentax MedicalAfsluttetEsophageal pladecelledysplasiKina
-
Military Institute of Medicine, PolandAfsluttet